JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Accueil・Liste d'Actions・Celldex Therapeutics Inc
Search

Celldex Therapeutics Inc

Ouvert

SecteurSoins de santé

32.16 -2.25

Achat Fort

Actualisation du prix 1 mai 2026, 19:59 UTC

AcheterVendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.08

Max

32.43

Chiffres clés

By Trading Economics

Revenu

-14M

-81M

Ventes

75K

75K

BPA

-1.22

Marge bénéficiaire

-108,422.667

Employés

198

EBITDA

-7.8M

-81M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+75.18% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1B

2.6B

Ouverture précédente

34.41

Clôture précédente

32.16

Sentiment de l'Actualité

By Acuity

50%

50%

176 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

18.91 / 20.63 Support & Résistance

Celldex Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mai 2026, 22:17 UTC

Résultats

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Lire

4 mai 2026, 23:47 UTC

Résultats

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Lire

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Lire

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Lire

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Lire

4 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Lire

4 mai 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Lire

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Lire

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Lire

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Lire

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Shareholders to Own About 51% of Combined Company

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Deal Unanimously Recommended by Vault Board

DJ

Lire

4 mai 2026, 22:39 UTC

Acquisitions, Fusions, Rachats

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Lire

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Lire

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Lire

4 mai 2026, 22:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Lire

4 mai 2026, 22:26 UTC

Résultats
Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Lire

4 mai 2026, 22:02 UTC

Résultats

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Lire

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Lire

4 mai 2026, 21:52 UTC

Résultats

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Lire

4 mai 2026, 21:50 UTC

Résultats

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Lire

4 mai 2026, 21:50 UTC

Résultats

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Lire

4 mai 2026, 21:49 UTC

Résultats

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Lire

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Lire

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Lire

4 mai 2026, 21:43 UTC

Résultats

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Lire

4 mai 2026, 21:41 UTC

Résultats

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Lire

4 mai 2026, 21:40 UTC

Résultats

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Lire

Comparaison

Variation de prix

Celldex Therapeutics Inc prévision

Objectif de Prix

By TipRanks

75.18% hausse

Prévisions sur 12 Mois

Moyen 56.6 USD  75.18%

Haut 90 USD

Bas 34 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

1

Maintien

0

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

18.91 / 20.63Support & Résistance

Court Terme

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Moyen Terme

Bullish Evidence

Recent bullish events outweigh bearish events.

Long Terme

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

176 / 347Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Autres valeurs du secteur

JNJ

Johnson and Johnson

225.57

↑ +0.63%

UNH

UnitedHealth Group Inc

363.82

↓-1.87%

TMO

Thermo Fisher Scientific Inc

466.62

↑ +0.92%

ISRG

Intuitive Surgical Inc

451.55

↓-0.21%

ABT

Abbott Laboratories

87.15

↓-0.47%
help-icon Live chat